BUSINESS● LOWJul 27 · Jul 27, 2026, 11:49 AM
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data
Seeking Alpha Tech
MapLight Therapeutics' stock price dropped significantly following the release of mixed phase 2 data for its schizophrenia treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS32m agoJapan exports post huge miss in September as growth slows to 16.7%CNBCBUSINESS34m agoWhy Anthropic has a major China problem ahead of its blockbuster IPOSouth China Morning Post